INTRASENSE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.295 EUR | -6.65% |
|
-10.61% | -18.06% |
| Apr. 17 | Intrasense: an innovative solution for cancer monitoring | CF |
| Apr. 09 | Guerbet: CE certificate for a platform | CF |
| Sales 2022 | 3.79M 4.06M | Sales 2023 | 3.3M 3.54M | Capitalization | 18.8M 20.12M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -3.21M | Net income 2023 | -3M -3.21M | EV / Sales 2022 | 2.85 x |
| Net Debt 2022 | 650K 696K | Net cash position 2023 | 3.06M 3.28M | EV / Sales 2023 | 4.76 x |
| P/E ratio 2022 |
-2.97
x | P/E ratio 2023 |
-5.16
x | Employees | 74 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -6.65% | ||
| 1 week | -10.61% | ||
| Current month | +28.26% | ||
| 1 month | +28.26% | ||
| 3 months | -12.72% | ||
| 6 months | -31.40% | ||
| Current year | -18.06% |
1 week
0.28
0.36
1 month
0.210.44
Current year
0.200.44
1 year
0.200.55
3 years
0.201.02
5 years
0.202.43
10 years
0.194.10
| Managers | Title | Age | Since |
|---|---|---|---|
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 18-02-11 |
Julien Coste
DFI | Director of Finance/CFO | - | - |
Frédéric Champ
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michèle Lesieur
CHM | Chairman | 65 | 20-10-07 |
Patrice Rullier
BRD | Director/Board Member | 63 | 19-03-14 |
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 18-02-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.295 | -6.65% | 75,232 |
| 24-04-26 | 0.316 | -3.66% | 49,262 |
| 24-04-25 | 0.328 | -1.20% | 45,402 |
| 24-04-24 | 0.332 | +1.84% | 12,525 |
| 24-04-23 | 0.326 | -1.21% | 3,451 |
Real-time Euronext Paris, April 29, 2024 at 11:35 am EDT
More quotes
Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1,200 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system.
Calendar
2024-07-10
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.06% | 17.61M | |
| +8.69% | 219B | |
| +6.69% | 183B | |
| +10.90% | 133B | |
| +25.41% | 108B | |
| +0.27% | 63.06B | |
| +12.72% | 52.02B | |
| +3.96% | 48.2B | |
| +0.40% | 40.37B | |
| +15.03% | 39.35B |
- Stock Market
- Equities
- ALINS Stock
